(Q73505916)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

1 reference

O Stål

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

A Borg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Fernö

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

A C Källström

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P Malmström

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

B Nordenskjöld

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

South Sweden Breast Cancer Group. Southeast Sweden Breast Cancer Group

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

1545-1550

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Multiple splicing variants of the estrogen receptor are present in individual human breast tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

HER-2/neu oncogene protein and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313310474

7 January 2021

Identifiers

DOI

10.1023/A:1008313310474

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205461%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference